Detailed Information on Publication Record
2008
Current status of Japanese HIV-infected patients with coagulation disorders : coinfection with both HIV and HCV
TATSUNAMI, Shinobu, Junichi MIMAYA, Akira SHIRATA, Jiří ZELINKA, Ivanka HOROVÁ et. al.Basic information
Original name
Current status of Japanese HIV-infected patients with coagulation disorders : coinfection with both HIV and HCV
Name in Czech
Současný stav japonských HIV pacientů s poruchou koagulace: koinfekce HIV i HCV
Authors
TATSUNAMI, Shinobu (392 Japan), Junichi MIMAYA (392 Japan), Akira SHIRATA (392 Japan), Jiří ZELINKA (203 Czech Republic), Ivanka HOROVÁ (203 Czech Republic, guarantor), Jugo HANAI (392 Japan), Yukata NISHINA (392 Japan), Katsumi OHIRA (392 Japan) and Masashi TAKI (392 Japan)
Edition
International Journal of Hematology, Japonsko, Springer, 2008, 0925-5710
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30200 3.2 Clinical medicine
Country of publisher
Japan
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Impact factor
Impact factor: 1.283
RIV identification code
RIV/00216224:14310/08:00027284
Organization unit
Faculty of Science
UT WoS
000259910200012
Keywords in English
Hemophiliacs; Coagulation disorders; HIV; HCV; Survival; Surveillance
Tags
Tags
Reviewed
Změněno: 23/6/2009 10:26, Mgr. Jiří Zelinka, Dr.
V originále
We herein report on the current status of Japanese HIV-positive patients with coagulation disorders, primarily hemophilia, based on the national survey of 31 May 2006. The total number of registered patients was 1,431 (Hemophilia A 1,086; Hemophilia B 325; von Willebrand disease 8; others 12), and 604 of these patients were deceased by 31 May 2006. The survival rate after the beginning of 1983 was evaluated by the Kaplan-Meier method. The total number of surviving patients was 827, and the survival rate on 31 May 2006 was 55.7 +- 1.4%. Among the 827 surviving patients, HCV antibody was observed in 740, was negative in 16, and was not reported in 71 patients. Thus, the prevalence of HCV infection was 98% in the surviving patients based on the presence of HCV antibody. Among the 604 deceased patients, liver disease was reported as a cause of death in 149 cases (25%), and infection with HCV was reported as the possible cause of liver disease in 120 cases (20%). After 1997, 63 cases among the subtotal of 148 deaths had critical hepatic disease that originated from HCV infection, which accounted for 43% of the subtotal. The cumulative rate of patients who received interferon therapy was 32%. Interferon therapy should be prescribed more frequently to HIV-positive patients with coagulation disorders in order to realize the survival benefits, although clinicians should be aware of side effects and toxicities.
In Czech
Je zdo podám výzkum stavu japonských HIV pacientů s poruchou koagulace.
Links
LC06024, research and development project |
|